Belief and bioavailability: a pharmacokinetically-driven analysis of Islamic fasting fatwas and its implications for clinical counselling

Technical Summary: Belief and Bioavailability

Problem Statement
During the holy month of Ramadan, over a billion Muslims fast from dawn to sunset. A significant number of patients with chronic conditions face a critical dilemma: they must choose between maintaining the religious validity of their fast and adhering to necessary medication regimens. Many patients autonomously alter or discontinue treatments based on religious rulings (fatwas) regarding which routes of drug administration invalidate the fast. These rulings are historically grounded in a classical anatomical framework centered on the concept of Jawf (the body cavity) and the entry of substances through open orifices.

The core problem identified is a potential disconnect between these classical anatomical criteria and modern pharmacological reality. Specifically, it is unclear whether the traditional framework accurately tracks the morally and physiologically relevant features of contemporary drug delivery systems. This ambiguity places clinicians in a difficult position, as they must counsel patients on matters sitting at the boundary of pharmacology and jurisprudence, often without clear empirical evidence to support or refute the religious premises. Consequently, patients may forgo effective treatment or make decisions based on mistaken empirical grounds regarding systemic drug exposure.

Methodology
This research employs a narrative, interdisciplinary analysis combining two distinct streams of inquiry:

1. Jurisprudential Analysis: The author retrieved and analyzed primary fatwas and consensus resolutions from three major contemporary Sunni jurisprudential bodies: the International Islamic Fiqh Academy (IIFA), Dar al-Iftaa al-Misriyyah (Egypt), and the General Iftaa Department of Jordan. A preliminary examination of the Saudi Permanent Committee was also conducted. The search focused on rulings concerning specific routes of administration (e.g., inhalers, transdermal patches, suppositories, injections).
2. Pharmacokinetic Analysis: The author evaluated these rulings against an established pharmacokinetic framework grounded in the two-compartment model and systemic bioavailability. Literature searches were conducted in PubMed, Scopus, and Google Scholar to identify quantitative bioavailability, systemic absorption, and deposition data for various drug delivery routes.

The study explicitly notes that a Large Language Model was used as an assistive tool for searching, proofreading, and structuring, but all claims and sources were independently verified by the author. The analysis is not a systematic review (no PRISMA protocol) but a purposive selection of sources relevant to the specific jurisprudential questions.

Key Contributions and Results
The paper synthesizes current religious rulings and maps them against pharmacokinetic evidence, revealing several areas of coherence and significant inconsistency:

• Coherence: Several rulings align with pharmacokinetic evidence. For instance, the permissibility of transdermal patches and non-nutritive parenteral preparations is consistent with the fact that these routes achieve systemic bioavailability without entering the body through a traditional open orifice.
• Inconsistencies in Pulmonary Delivery:
  • Inhalers: While Metered-Dose Inhalers (MDIs) are generally permitted, Dry Powder Inhalers (DPIs) are often ruled as fast-breaking. Pharmacokinetically, both are local-acting systems, though DPIs may deposit more carrier material in the throat. However, the distinction is pharmacokinetically nuanced.
  • Nebulizers vs. General Anesthesia: Nebulizers are unanimously deemed fast-breaking due to the volume of fluid reaching the lungs, whereas general anesthesia (which achieves complete systemic absorption) is ruled non-fast-breaking. This highlights a tension where the volume of delivery, rather than systemic intent or absorption, drives the ruling.
  • Smoking vs. Vaping: Both are prohibited, yet their pharmacokinetic profile (systemic absorption with minimal oropharyngeal deposition) is more similar to permitted general anesthesia than to prohibited nebulizers.
• Contradictions in Mucosal Absorption:
  • Rectal vs. Sublingual: The IIFA permits non-nutritive rectal suppositories despite significant systemic absorption (bypassing first-pass metabolism). Conversely, the conditional prohibition of sublingual tablets (based on incidental swallowing) ignores that sublingual absorption is predominantly transmucosal and highly bioavailable.
  • Ophthalmic vs. Nasal: The General Iftaa Department of Jordan rules eye drops as non-fast-breaking because the eye is not an orifice, disregarding nasolacrimal drainage. However, this same body rules nasal drops as fast-breaking if swallowed. This is a direct contradiction, as both routes share the nasolacrimal duct and potential for systemic absorption via the throat.
• Nutritive vs. Non-Nutritive Distinctions: The paper highlights that intravenous saline (non-nutritive) is permitted by some bodies but prohibited by others (e.g., Saudi Permanent Committee), despite achieving a therapeutic endpoint comparable to oral rehydration (which is prohibited).

Significance and Claims
The paper does not claim to adjudicate between jurisprudential positions or propose a new religious criterion. Instead, its significance lies in identifying the ethical and clinical consequences of the divergence between religious framings and pharmacological evidence.

• Clinical Implications: The author argues that when fast-invalidating rulings rest on empirical premises about anatomy and drug movement that pharmacological evidence no longer supports, patients may make decisions about their health and worship on inaccurate grounds. This affects medication adherence, therapeutic outcomes, and patient autonomy.
• Proposed Framework: The paper suggests that systemic bioavailability offers a more mechanistically coherent criterion for evaluating fast-breaking potential than the classical "orifice-entry" model. It posits that bioavailability provides an objective lens to inform, rather than replace, jurisprudential authority.
• Call for Interdisciplinary Dialogue: The primary contribution is a call for sustained dialogue between Islamic scholars, clinicians, and pharmaceutical scientists. The author cites the development of Jordan's 2014 Stem Cell Statute as a precedent where structured dialogue between empirical and jurisprudential expertise produced workable frameworks. They argue that medication use during Ramadan, affecting over a billion people annually, merits similar structured attention to ensure that patient autonomy is respected through the provision of accurate empirical information.

In conclusion, the paper asserts that respecting patient autonomy requires that decisions regarding medication during fasting rest on accurate empirical premises. Where religious rulings diverge from pharmacokinetic reality, clinicians have a concrete obligation to facilitate informed conversations that acknowledge both the religious authority and the pharmacological facts.